Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 7:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: vitamin K antagonist (VKA) Clear all
Completed Phase 3 Interventional Results available

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

NCT02234843
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 3 Interventional

SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism

NCT00062803
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
SR34006, (LMW)heparin, Warfarin VKA, Acenocoumarol VKA
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
54
States / cities
Loma Linda, California • San Diego, California • Aurora, Colorado + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 3 Interventional Results available

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

NCT02798471
View directory record Official record
Conditions
Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)
Interventions
Edoxaban, Standard of Care
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
1 Day to 17 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
22
States / cities
Tucson, Arizona • Los Angeles, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 3, 2026, 7:29 PM EDT
Active, not recruiting Not applicable Interventional

SIMPLAAFY Clinical Trial

NCT06521463
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
WATCHMAN FLX Pro LAAC Device
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
86
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)

NCT00067093
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
SanOrg34006, LMW heparin, Unfractionated heparin, Vitamin K antagonist (VKA)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
24
States / cities
Denver, Colorado • Jacksonville, Florida • Melbourne, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2011 · Synced Oct 3, 2026, 7:29 PM EDT
Completed No phase listed Observational

Real-world Comparative Effectiveness of Rivaroxaban Versus VKA

NCT02690155
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), VKA (Vitamin K antagonist)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
38,831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 3, 2026, 7:29 PM EDT
Completed No phase listed Observational Results available

RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism

NCT02596230
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
7,797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
19
States / cities
Long Beach, California • Miami, Florida • Pembroke Pines, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Oct 3, 2026, 7:29 PM EDT
Completed No phase listed Observational

Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist

NCT02687854
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Apixaban, Vitamin K antagonist
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
18,591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 3, 2026, 7:29 PM EDT
Completed No phase listed Observational

Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist

NCT02687867
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Dabigatran (Pradaxa), Vitamin K antagonist
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
56,039 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 3 Interventional Results available

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study

NCT00440193
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin followed by VKA
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
23
States / cities
Little Rock, Arkansas • Redlands, California • Bay Pines, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 3 Interventional Results available

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

NCT01674647
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
66
States / cities
Mobile, Alabama • Scottsdale, Arizona • East Palo Alto, California + 58 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 3 Interventional Results available

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

NCT00439777
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin overlapping with and followed by VKA
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
4,833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
23
States / cities
Little Rock, Arkansas • Redlands, California • Bay Pines, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 3 Interventional Results available

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

NCT01830543
View directory record Official record
Conditions
Atrial Fibrillation, Percutaneous Coronary Intervention
Interventions
rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg, aspirin (ASA), vitamin K antagonist (VKA), clopidogrel, prasugrel, ticagrelor
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
2,124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
86
States / cities
Huntsville, Alabama • Los Alamitos, California • Mission Viejo, California + 83 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 3, 2026, 7:29 PM EDT
Completed No phase listed Observational

An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding

NCT02319460
View directory record Official record
Conditions
Hemorrhage
Interventions
Kcentra®, Plasma
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
2,238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 3, 2026, 7:29 PM EDT
Active, not recruiting No phase listed Observational

Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure

NCT06429787
View directory record Official record
Conditions
Vitamin K-Dependent Coagulation Defect, Significant Bleeding Risk
Interventions
Balfaxar, Kcentra
Drug
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
3,574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 3, 2026, 7:29 PM EDT
Completed No phase listed Observational

Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients

NCT03374540
View directory record Official record
Conditions
Nonvalvular Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
78,517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Multiple Locations, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 3, 2026, 7:29 PM EDT
Terminated Phase 3 Interventional Results available

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

NCT02556203
View directory record Official record
Conditions
Transcatheter Aortic Valve Replacement
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic Acid (ASA), Clopidogrel, Vitamin K antagonist (VKA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
31
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Clearwater, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation

NCT02981472
View directory record Official record
Conditions
Thrombosis
Interventions
Apixaban, Vitamin K Antagonist (VKA), Low Molecular Weight Heparin (LMWH)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
28 Days to 17 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
14
States / cities
Phoenix, Arizona • La Jolla, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 4 Interventional Results available

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

NCT02415400
View directory record Official record
Conditions
Acute Coronary Syndromes
Interventions
Apixaban, vitamin K antagonist, Acetylsalicylic acid, Acetylsalicylic acid placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 95 Years
Enrollment
4,614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
143
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 3, 2026, 7:29 PM EDT
Not listed Phase 3 Interventional

Effect of TXA Oral Sol 5% in Patients Treated With DOACs or VKA and Undergoing a Single or Multiple Tooth Extraction

NCT06143787
View directory record Official record
Conditions
Bleeding From Teeth, Bleeding Prophylaxis
Interventions
Tranexamic acid
Drug
Lead sponsor
Hyloris Developments
Industry
Eligibility
18 Years to 99 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Loma Linda, California • Stamford, Connecticut • Millcreek, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 3, 2026, 7:29 PM EDT
Recruiting Phase 3 Interventional

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

NCT04045665
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
51
States / cities
Little Rock, Arkansas • Los Angeles, California • Stanford, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 3 Interventional Results available

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

NCT02740335
View directory record Official record
Conditions
Significant Bleeding Risk
Interventions
Octaplex, Beriplex P/N (Kcentra)
Drug
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
22
States / cities
Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 2 Interventional

Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis

NCT00395772
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Xarelto (Rivaroxaban, BAY59-7939), (LMW) Heparin + Vitamin K Antagonist
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
5
States / cities
Albuquerque, New Mexico • Chapel Hill, North Carolina • Fredericksburg, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 3 Interventional Results available

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

NCT01729871
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
rivaroxaban, uninterrupted vitamin K antagonist (VKA)
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
24
States / cities
Beverly Hills, California • Los Angeles, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 3, 2026, 7:29 PM EDT